Post by David Grey on Apr 24, 2020 12:36:16 GMT -5
A phase 3, multicenter, randomizd, double-blind, placebocontrolled, clinical study to assess the efficacy and safety of linzagolix in subjects with moderate to severe endometriosis associated pain.
304 Ne 1St Street Old Town, FL 32626
View Study Website Sponsored By: Southeast Clinical Research.net Stipend: $10 - $100 Length of Study: 60 weeks Research Facility: Out-Patient Gender: Both Age: 1 - 100 Washout Period: 90 days from Last Dosing Date to Admission Health Condition: Endometriosis
More Information: Diagnosed with pelvic endometriosis in the last 10 years with supporting documentation in medical records.
BMI of >/= 18 and regular menstral cycle.
Moderate to severe endometriosis associated pain during screening period reported in electronic diary with 75% completion of diary.